---
title: "Sandoz will pay $450 million to settle generic price-fixing claims and says its outlook is unchanged."
publication: The Precedent
section: "Antitrust"
date: 2026-09-12
url: https://theprecedent.org/article/sandoz-will-pay-450-million-to-settle-generic-price-fixing-claims-and-says-its-o
---

# Sandoz will pay $450 million to settle generic price-fixing claims and says its outlook is unchanged.

*The deal carries no admission. The company had already reserved for it.*

Sandoz and its Fougera unit agreed on August 3, 2026, to settle with 43 states and territories over alleged price-fixing and market allocation in generic drugs. They will pay $400 million over seven years from 2027, plus about $50 million to states that settled earlier. A further $28.5 million would settle with indirect resellers.

This is not the first payment. Sandoz's former parent, Novartis, paid $195 million in 2020 to resolve a federal criminal claim and $185 million on the civil side. Sandoz paid $265 million to purchaser classes in 2024.

Sandoz says none of it affects 2026 guidance or its mid-term outlook. That is the point. More than $1 billion across four resolutions has been absorbed as a cost of doing business, with the payments spread out to 2033.

The people who overpaid were patients and Medicaid programs buying everyday generics. They are being repaid slowly, by a company that concedes nothing.

## Sources

1. https://www.pharmexec.com/view/sandoz-agrees-450-million-settlement-43-us-states-over-generic-drug-antitrust-claims
2. https://pharmaphorum.com/news/sandoz-will-pay-another-480m-settle-us-antitrust-suits

---
Cite as: The Precedent. "Sandoz will pay $450 million to settle generic price-fixing claims and says its outlook is unchanged.." September 12, 2026. https://theprecedent.org/article/sandoz-will-pay-450-million-to-settle-generic-price-fixing-claims-and-says-its-o
